We put patients at the center of everything we do.
Strengthening Our Leading GI Portfolio
Apraglutide
In June 2023, we expanded our pipeline through the acquisition of VectivBio to include apraglutide, an investigational GLP-2 analog being evaluated as a potential once-weekly treatment for patients with Short Bowel Syndrome with intestinal failure (SBS-IF).
SBS-IF is a severe malabsorptive condition requiring ongoing I.V. administration of fluids and nutrients and is associated with significant morbidity and mortality, high economic burden, and an impaired quality of life. A substantial number of SBS-IF patients remain dependent on chronic parenteral support, and there is considerable unmet need in this patient population, which has an estimated addressable population of 18,000 adult patients across the U.S., Europe, and Japan.
CNP-104
IW-3300
Patient Engagement
We believe in bringing diverse patient voices to the forefront of what we do, and we are committed to reducing healthcare inequities. In 2021, we sponsored a workshop with the International Foundation for Gastrointestinal Disorders (IFFGD) focused on improving communication between physicians and patients living with GI disease. We also partnered with the digital platform PatientsLikeMe to bolster support for patient advocacy. Our clinical trials are designed to minimize patient burden and improve access to investigational drugs by all demographics.
Responsible Research
Clinical Research Data Sharing
We meet industry and scientific standards in our clinical trial publication and data sharing practices, and we believe providing access to such data, to the extent permissible under relevant law, strengthens opportunities for further scientific development and collaboration. All clinical trials results, including the results of terminated trials, when required, are published on clinicaltrials.gov and clinicaltrialsregister.eu.
To uphold our commitments to patient privacy, we have implemented and maintain a Clinical Research Data Sharing Policy, which requires that individual participant data that underlie the results reported in any publication of any Ironwood clinical study will be shared only after deidentification.
Animal Welfare
We are committed to the ethical use of animals in medical research. All animal studies are carefully reviewed by an Institutional Animal Care and Use Committee (IACUC) which is charged with ensuring that a proposed study is essential. We comply with the “Three Rs” (Replace, Reduce and Refine), widely accepted ethical principles that are embedded in the conduct of animal-based science.
Collaborating Opportunities
As a GI-focused, global healthcare company, we are interested in identifying opportunities to collaborate on GI products. Please contact [email protected] for partnership inquiries. Learn more about grant and sponsorship opportunities.
